NAII

Business Context and Reporting Period

Company: Natural Alternatives International, Inc. (NAI)
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2003
Business Overview: NAI provides private label contract manufacturing and direct-to-consumer marketing services for vitamins, minerals, herbs, and nutritional supplements. Operations are based in San Marcos and Vista, California, with a wholly-owned subsidiary (NAIE) operating a manufacturing and distribution facility in Manno, Switzerland.

Key Financial Metrics (Fiscal Year 2003)

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 12% to $55.96 million from $50.04 million in fiscal 2002. Private label contract manufacturing sales rose 10%, while direct-to-consumer sales grew 22% due to new product introductions.
• Profitability: Operating income improved significantly to $1.17 million from $285,000 in the prior year, driven by a gross margin expansion from 22% to 24%.
• Net Income Volatility: Reported net income decreased to $1.11 million from $3.88 million in fiscal 2002. This decline is primarily attributable to the absence of a $3.41 million one-time gain from vitamin antitrust litigation proceeds recorded in fiscal 2002 (compared to $225,000 in fiscal 2003).
• Liquidity: Working capital increased to $12.32 million from $8.73 million. Cash and cash equivalents rose to $5.48 million, aided by a new $6.5 million credit facility and the collection of a $701,000 income tax refund.
• Debt Structure: Total debt increased to $3.0 million. The company entered a new two-year credit facility in October 2002, replacing a previous line of credit and refinancing a term note.

Outlook, Risks, and Management Commentary

• Guidance & Strategy: Management plans to increase capital expenditures in fiscal 2004 by over 50% to expand encapsulation and packaging capacity. The company intends to fund working capital and debt payments through operating cash flow.
• Customer Concentration Risk: The company relies heavily on two major customers. NSA International, Inc. accounted for 43% of net sales, and Mannatech Incorporated accounted for 27% in fiscal 2003. The loss of either would materially affect operations.
• Supplier Concentration: Carrington Laboratories Incorporated was the largest supplier, providing 35% of total raw material purchases.
• Regulatory & Market Risks: Operations are subject to extensive FDA and FTC regulations. The company faces risks related to adverse publicity regarding nutritional supplements, product liability claims, and the inability to raise additional capital if needed.
• Foreign Currency: The company is exposed to exchange rate fluctuations between the U.S. dollar, Swiss Franc, and Euro. A 10% adverse change in these rates would have decreased earnings by approximately $489,000.
• Tax Position: A full valuation allowance of $1.6 million was recorded against net deferred tax assets due to historical operating losses and uncertainty regarding near-term taxable income.

Investor Verification Checklist

• Customer Dependency: Verify the stability of relationships with NSA International and Mannatech, which collectively represent 70% of revenue.
• Recurring Income Quality: Assess core operating profitability excluding the one-time vitamin antitrust litigation proceeds ($225k in 2003 vs. $3.41M in 2002).
• Debt Covenants: Review the terms of the new $6.5 million credit facility to ensure compliance with covenants and availability of the $4.0 million working capital line.
• Inventory Valuation: Monitor inventory reserves given the company's policy to record valuation reserves for excess and obsolete inventory based on future demand assumptions.
• Capital Expenditure Plan: Confirm the execution of the planned >50% increase in capital expenditures for fiscal 2004 to expand capacity.